{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T19:13:01Z","timestamp":1791054781745,"version":"4.1.0"},"reference-count":37,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2001,12,1]]},"abstract":"<jats:p>PURPOSE: We investigated the number, phenotype, and prognostic significance of CD8+ T cells in patients with mycosis fungoides (MF) and CD30\u2212 primary cutaneous large T-cell lymphoma (PCLTCL).<\/jats:p><jats:p>PATIENTS AND METHODS: Immunohistochemical stainings for CD8, granzyme B (GrB), T cell\u2013restricted intracellular antigen (TIA-1), Fas ligand (FasL), and killer-cell inhibitory receptors (KIRs; CD95, CD158a, and CD158b) were performed on 83 first-diagnostic biopsy samples obtained from patients with plaque-stage MF (n = 42), tumor-stage MF (n = 20), and CD30\u2212 PCLTCL (n = 21).<\/jats:p><jats:p>RESULTS: Serial sections and double-staining experiments showed that the large majority of CD8+ T cells in MF and CD30\u2212 PCLTCL expressed TIA-1 and FasL, whereas only a minority expressed GrB, which suggested that these CD8+ T cells were partly activated cytotoxic T lymphocytes (CTLs). These CD8+ CTLs never or rarely expressed KIRs. This phenotype was a constant feature of CD8+ CTLs and did not alter with disease progression. In contrast, the median percentage of CD8+ CTLs in plaque-stage MF (22%), tumor-stage MF (7%), and CD30\u2212 PCLTCL (3%) differed significantly (P &lt; .0001) and was associated with a significant decrease in 5-year survival. Also within the group of tumor-stage MF, a significant relation between CD8+ CTLs and survival was found. Multivariate analysis in the total group of MF demonstrated that both skin stage and percentage of CD8+ CTLs were independent parameters of survival.<\/jats:p><jats:p>CONCLUSION: Our results demonstrated that partly activated CD8+ CTLs were present in CTCL and that high proportions of these cells correlated with a better prognosis. This suggested that these CD8+ CTLs could play an important role in the antitumor response in these conditions.<\/jats:p>","DOI":"10.1200\/jco.2001.19.23.4322","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T07:35:27Z","timestamp":1487921727000},"page":"4322-4329","source":"Crossref","is-referenced-by-count":100,"title":["CD8+ T Cells in Cutaneous T-Cell Lymphoma: Expression of Cytotoxic Proteins, Fas Ligand, and Killing Inhibitory Receptors and Their Relationship With Clinical Behavior"],"prefix":"10.1200","volume":"19","author":[{"given":"Maarten H.","family":"Vermeer","sequence":"first","affiliation":[{"name":"From the Departments of Dermatology and Pathology, Free University Hospital, Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remco","family":"van Doorn","sequence":"additional","affiliation":[{"name":"From the Departments of Dermatology and Pathology, Free University Hospital, Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Dukers","sequence":"additional","affiliation":[{"name":"From the Departments of Dermatology and Pathology, Free University Hospital, Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel W.","family":"Bekkenk","sequence":"additional","affiliation":[{"name":"From the Departments of Dermatology and Pathology, Free University Hospital, Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris J.L.M.","family":"Meijer","sequence":"additional","affiliation":[{"name":"From the Departments of Dermatology and Pathology, Free University Hospital, Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rein","family":"Willemze","sequence":"additional","affiliation":[{"name":"From the Departments of Dermatology and Pathology, Free University Hospital, Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1-097579","unstructured":"Willemze R, Kerl H, Sterry W, et al: EORTC classification for primary cutaneous lymphomas: A proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 90: 354,1997-371,"},{"key":"R2-097579","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.136.4.504"},{"key":"R3-097579","doi-asserted-by":"crossref","unstructured":"Rook AH, Yoo EK, Grossman DJ, et al: Use of biological response modifiers in the treatment of cutaneous T-cell lymphoma. Curr Opin Oncol 10: 170,1998-174,","DOI":"10.1097\/00001622-199803000-00015"},{"key":"R4-097579","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12363378"},{"key":"R5-097579","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19980504)76:3<304::AID-IJC3>3.0.CO;2-Z"},{"key":"R6-097579","doi-asserted-by":"crossref","unstructured":"Bagot M, Echchakir H, Mami-Chouaib F, et al: Isolation of tumor-specific cytotoxic CD4+ and CD4+ CD8dim+ T-cell clones infiltrating a cutaneous T-cell lymphoma. Blood 11: 4331,1998-4341,","DOI":"10.1182\/blood.V91.11.4331.411k12_4331_4341"},{"key":"R7-097579","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2000.00995.x"},{"key":"R8-097579","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(87)70168-6"},{"key":"R9-097579","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(95)90067-5"},{"key":"R10-097579","doi-asserted-by":"publisher","DOI":"10.1126\/science.7518614"},{"key":"R11-097579","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-7915(98)80222-7"},{"key":"R12-097579","doi-asserted-by":"crossref","unstructured":"Anderson P, Nagler-Anderson C, O\u2019Brien C, et al: A monoclonal antibody reactive with a 15-kDa cytoplasmic granule-associated protein defines a subpopulation of CD8+ T lymphocytes. J Immunol 144: 574,1990-582,","DOI":"10.4049\/jimmunol.144.2.574"},{"key":"R13-097579","doi-asserted-by":"crossref","unstructured":"Anderson P: TIA-1 structural and functional studies on a new class of cytolytic effector molecule. Curr Top Microbiol Immunol 198: 131,1995-143,","DOI":"10.1007\/978-3-642-79414-8_8"},{"key":"R14-097579","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(91)90145-J"},{"key":"R15-097579","doi-asserted-by":"crossref","unstructured":"Krahenbuhl O, Rey C, Jenne D, et al: Characterization of granzymes A and B isolated from granules of cloned human cytotoxic T lymphocytes. J Immunol 141: 3471,1988-3477,","DOI":"10.4049\/jimmunol.141.10.3471"},{"key":"R16-097579","doi-asserted-by":"publisher","DOI":"10.1084\/jem.182.3.875"},{"key":"R17-097579","doi-asserted-by":"publisher","DOI":"10.1084\/jem.180.2.545"},{"key":"R18-097579","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.22.12433"},{"key":"R19-097579","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2000.00195.x"},{"key":"R20-097579","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(93)90241-X"},{"key":"R21-097579","doi-asserted-by":"crossref","unstructured":"Kummer JA, Kamp AM, Tadema TM, et al: Localization and identification of granzymes A- and B-expressing cells in normal human lymphoid tissue and peripheral blood. Clin Exp Immunol 100: 164,1995-172,","DOI":"10.1111\/j.1365-2249.1995.tb03619.x"},{"key":"R22-097579","unstructured":"Oudejans JJ, Kummer JA, Jiwa NM, et al: Granzyme B expression in Reed-Sternberg cells of Hodgkin\u2019s disease. Am J Pathol 148: 233,1996-240,"},{"key":"R23-097579","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9896(199912)189:4<533::AID-PATH473>3.0.CO;2-3"},{"key":"R24-097579","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.4.1376"},{"key":"R25-097579","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.54.3.224"},{"key":"R26-097579","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/4.4.529"},{"key":"R27-097579","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.52.2.129"},{"key":"R28-097579","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65372-2"},{"key":"R29-097579","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12337633"},{"key":"R30-097579","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.1995.tb00684.x"},{"key":"R31-097579","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0560.1994.tb00250.x"},{"key":"R32-097579","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65144-9"},{"key":"R33-097579","doi-asserted-by":"publisher","DOI":"10.1016\/0952-7915(95)80023-9"},{"key":"R34-097579","doi-asserted-by":"publisher","DOI":"10.1016\/0952-7915(95)80108-1"},{"key":"R35-097579","doi-asserted-by":"publisher","DOI":"10.1007\/s004030050234"},{"key":"R36-097579","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03656.x"},{"key":"R37-097579","doi-asserted-by":"publisher","DOI":"10.1084\/jem.190.6.775"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2001.19.23.4322","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T10:29:22Z","timestamp":1692700162000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2001.19.23.4322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,12,1]]},"references-count":37,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2001,12,1]]}},"alternative-id":["10.1200\/JCO.2001.19.23.4322"],"URL":"https:\/\/doi.org\/10.1200\/jco.2001.19.23.4322","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,12,1]]}}}